Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 157–158
HOS-214911 · Präparat HOS-155350
157 MedDRA system organ Very common adverse Common adverse reactions classes reactions Respiratory, thoracic and Pharyngolaryngeal pain Dyspnoea (G3/4: 1%); mediastinal disorders (G3/4: 2%) Cough (G3/4: < 1%); Epistaxis (G3/4: < 1%) Gastrointestinal disorders Stomatitis (G3/4: 18%); Abdominal pain upper; Diarrhoea (G3/4: 14%); Dry mouth Nausea (G3/4: 6%); Vomiting (G3/4: 4%); Constipation (G3/4: 1%); Abdominal pain (G3/4: 2%); Dyspepsia Skin and subcutaneous tissue Hand-foot syndrome Dermatitis; disorders (G3/4: 24%); Rash erythematous Alopecia (G3/4: 6%); (G3/4: < 1%); Nail disorders (G3/4: 2%) Nail discolouration; Onycholysis (G3/4: 1%) Musculoskeletal and Myalgia (G3/4: 2%); Pain in extremity (G3/4: < 1%); connective tissue disorders Arthralgia (G3/4: 1%) Back pain (G3/4: 1%) General disorders and Asthenia (G3/4: 3%); Lethargy; administration site conditions Pyrexia (G3/4: 1%); Pain Fatigue/weakness (G3/4: 5%); Oedema peripheral (G3/4: 1%) Investigations Weight decreased; G3/4 Blood bilirubin increased (9%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 6c1619682293e2562d417efb4b626bcc3de43023a97653289ff226f2e6745bd6 · Zeichen 20919–22852 im Abschnitt